PRAX
Praxis Precision Medicines Inc
NASDAQ: PRAX · HEALTHCARE · BIOTECHNOLOGY
$331.81
-4.06% today
Updated 2026-06-05
Market cap
$7.43B
P/E ratio
—
P/S ratio
953.14x
EPS (TTM)
$-13.38
Dividend yield
—
52W range
$37 – $367
Volume
0.4M
WallStSmart proprietary scores
33
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
6.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$627.59
+89.14%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy13 Buy1 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 6.75 — safe zone
+ Revenue growth 1,349.00% QoQ
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-86.11M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.46M | $2.45M | $8.55M | $0.00 | $7.46M |
| Net income | $-213.07M | $-123.28M | $-182.82M | $-303.27M | $-92.56M |
| EPS | — | — | — | — | $-13.38 |
| Free cash flow | $-185.49M | $-111.19M | $-131.76M | $-249.12M | $-86.11M |
| Profit margin | -14,554.10% | -5,037.88% | -2,137.48% | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-14 | SOUZA, MARCIO | Buy | 126 | $167.94 |
| 2026-05-14 | SNIECINSKI, MEGAN | Buy | 89 | $167.94 |
| 2026-05-14 | NEMIROFF, ALEX | Buy | 78 | $167.94 |
Peer comparison
Smart narrative
Praxis Precision Medicines Inc trades at $331.81. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 6.75, it sits in the safe zone. TTM revenue stands at $7.46M.
Frequently asked questions
What is Praxis Precision Medicines Inc's stock price?
Praxis Precision Medicines Inc (PRAX) trades at $331.81, on a P/S of 953.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Praxis Precision Medicines Inc overvalued?
Praxis Precision Medicines Inc carries a Smart Value Score of 33/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Praxis Precision Medicines Inc (PRAX)?
The 12-month analyst consensus target is $627.59, about 89.1% above the current $331.81. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Praxis Precision Medicines Inc's revenue?
Praxis Precision Medicines Inc's trailing twelve-month revenue is $7.46M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Praxis Precision Medicines Inc's Altman Z-Score is 6.75, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio953.14x
ROE-23.16%
Beta2.75
50D MA$319.49
200D MA$240.85
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—